Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
23 2월 2024 - 6:05AM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the
“Company”), an eyecare technology company focused on developing and
commercializing innovative, interventional technologies intended to
transform care and improve patients' lives, today announced it will
report financial results for the fourth quarter and full year ended
December 31, 2023, after the market close on Thursday, March 7,
2024. The Company’s management will discuss the results during a
conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m.
Eastern Time.
Investors interested in listening to the
conference call may do so by accessing a live and archived webcast
of the event at www.sightsciences.com, on the Investors page in the
News & Events section. The webcast will be available for replay
for at least 90 days after the event.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative and interventional technologies intended
to transform care and improve patients' lives. Using minimally
invasive or non-invasive approaches to target the underlying causes
of the world's most prevalent eye diseases, Sight Sciences seeks to
create more effective treatment paradigms that enhance patient care
and supplant conventional outdated approaches. The Company's OMNI®
Surgical System is an implant-free glaucoma surgery technology (i)
indicated in the United States to reduce intraocular pressure in
adult patients with primary open-angle glaucoma; and (ii) CE Marked
for the catheterization and transluminal viscodilation of Schlemm’s
canal and the cutting of trabecular meshwork to reduce intraocular
pressure in adult patients with open-angle glaucoma. Glaucoma is
the world's leading cause of irreversible blindness. The Company's
TearCare® System technology is 510(k) cleared in the United
States for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (“MGD”) when used in conjunction with manual expression
of the meibomian glands, enabling clearance of gland obstructions
by physicians to address the leading cause of dry eye disease. The
Company's SION® Surgical Instrument is a manually operated device
available in the United States to be used in ophthalmic surgical
procedures to excise trabecular meshwork.
For more information,
visit http://www.sightsciences.com.
Sight Sciences and TearCare are trademarks of Sight Sciences
registered in the United States. OMNI, OMNI ERGO, and SION are
trademarks of Sight Sciences registered in the United States,
European Union and other territories.
© 2024 Sight Sciences. All rights reserved.
Media contact:
pr@SightSciences.com
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sight Sciences (NASDAQ:SGHT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024